PEPTIDEREPORT

Video claim watch

Mounjaro (tirzepatide): The newest diabetes and obesity medication

Medical doctor explainer on tirzepatide mechanism and clinical context.

Christopher McGowan, MD channel10:00 runtime315K views when checked

Published Jan 1, 2023. Metadata checked Jul 1, 2026.

Watch on YouTube

Transcript review

6 material claims logged

Editorial review complete audit stateauto-captioned transcript0 operational-guidance flags0 source gaps

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

generally accurate for its recording date, but all status language must be historically labeled.

auto-caption available; 9 creator chapters.

Claim-by-claim audit

What the video says, and what needs checking

00:00:20
High-risk evidence claimHigh-risk regulatory claim

Calls tirzepatide the most effective obesity medication developed and notes it was then approved for diabetes, not obesity.

Review topic: tirzepatide / historical status.

Checked against: Tirzepatide once weekly for the treatment of obesity

current pages must note later Zepbound approval.

Connected research

Compounds discussed

Tirzepatide Tirzepatide is a dual GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound for specific FDA-approved indications. Randomized trials support diabetes and chronic weight-management uses. Public discussion should remain separate from label language and trial populations.

Source check

Records used in this claim audit